Taysha Gene Therapies (TSHA) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Research and Development Expenses: $25.7 million for Q3 2025, up from $14.9 million in Q3 2024, driven by manufacturing initiatives and clinical trial activities.

General and Administrative Expenses: $8.3 million, slightly higher than $7.9 million in the prior year, primarily due to debt issuance costs.

Net Loss: $32.7 million, or $0.09 per share, compared to a net loss of $25.5 million, or $0.10 per share, in Q3 2024.

Cash Position: $297.3 million as of September 30, 2025, expected to support operations into 2028.

2Strategic Updates and Business Highlights

Regulatory Progress: Received FDA Breakthrough Therapy designation for TSHA-102 for Rett syndrome, emphasizing the unmet medical need and potential for significant improvement over existing treatments.

Clinical Trials: Finalized alignment with the FDA on the REVEAL pivotal trial protocol, with plans to dose the first patient this quarter. The trial aims to enroll 15 patients, with a primary endpoint of a 33% response rate based on developmental milestones.

Data Strength: Part A of the REVEAL trials showed a 100% response rate in milestone achievement among 10 patients, reinforcing the potential efficacy of TSHA-102.

Commercial Leadership: Appointment of David McNinch as Chief Commercial Officer to strengthen the commercial strategy ahead of potential product launch.

3Forward Guidance and Outlook

Enrollment Timeline: Anticipated to enroll 15 patients within 3 to 6 months, with the first patient dosing scheduled for this quarter.

Long-term Data Reporting: Expect to report longer-term clinical data from Part A in the first half of 2026.

BLA Submission: The interim analysis at 6 months may allow for an accelerated BLA submission by at least two quarters, contingent on achieving the primary endpoint.

4Bad News, Challenges, or Points of Concern

Increased Expenses: Rising R&D costs may impact financial sustainability as the company progresses through trials.

Regulatory Risks: While the FDA has provided alignment, any changes in regulatory guidance or unexpected trial results could pose risks to timelines and approval.

Market Competition: The gene therapy space is competitive, with potential entrants that could impact market dynamics and pricing strategies.

5Notable Q&A Insights

High Demand for Trials: There is significant interest from patients and advocacy groups for participation in the pivotal trial, with over 15 sites identified, each having a substantial number of eligible patients.

FDA Interaction: Management expressed confidence in their ongoing relationship with the FDA, highlighting constructive engagement and alignment on trial protocols.

Younger Patient Cohort: Plans to include 2- to 5-year-olds in the BLA submission process, with a focus on establishing safety first before collecting efficacy data.

Statistical Rigor: The trial's design emphasizes objective evaluations of milestone gains through video assessments by blinded reviewers, which management believes will support a strong case for efficacy. This summary encapsulates Taysha Gene Therapies' current financial health, strategic initiatives, and outlook while addressing potential risks and insights from the Q&A session.